Gemcitabine plus concurrent irreversible electroporation gemcitabine alone for locally advanced pancreatic cancer.

BACKGROUND

Locally advanced pancreatic cancer (LAPC) is a common malignant digestive system tumor that ranks as the fourth leading cause of cancer-related death in the world. The prognosis of LAPC is poor even after standard treatment. Irreversible electroporation (IRE) is a novel ablative strategy for LAPC. Several studies have confirmed the safety of IRE. To date, no prospective studies have been performed to investigate the therapeutic efficacy of conventional gemcitabine (GEM) plus concurrent IRE.

AIM

To compare the therapeutic efficacy between conventional GEM plus concurrent IRE and GEM alone for LAPC.

METHODS

From February 2016 to September 2017, a total of 68 LAPC patients were treated with GEM plus concurrent IRE = 33) or GEM alone = 35). Overall survival (OS), progression free survival (PFS), and procedure-related complications were compared between the two groups. Multivariate analyses were performed to identify any prognostic factors.

RESULTS

There were no treatment-related deaths. The technical success rate of IRE ablation was 100%. The GEM + IRE group had a significantly longer OS from the time of diagnosis of LAPC (19.8 mo 9.3 mo, < 0.0001) than the GEM alone group. The GEM + IRE group had a significantly longer PFS (8.3 mo 4.7 mo, < 0.0001) than the GEM alone group. Tumor volume less than 37 cm and GEM plus concurrent IRE were identified as significant favorable factors for both the OS and PFS.

CONCLUSION

Gemcitabine plus concurrent IRE is an effective treatment for patients with LAPC.